Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 210-213

  Rose, Peter G ^a,b   Blessing, John A ^c   Lele, Shashikant ^c   Abulafia, Ovadia ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Cervical cancer; Chemotherapy; Liposomal doxorubicin

Indexed keywords

DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTOPENIA; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; UTERINE CERVICAL NEOPLASMS;

EID: 33745897362     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.048     Document Type: Article

References (24)

1. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., and Major F.J. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 3 (1985) 1079-1085
2. Thigpen T., Shingleton H., Homesley H., Lagasse L., and Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48 (1981) 899-903
3. Thigpen J.T., Blessing J.A., DiSaia W.C., and Hatch K.D. A randomized comparison of a rapid versus prolonged (24-hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 32 (1989) 198-202
4. Omura G.A., Blessing J.A., Vaccarello L., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 15 (1997) 165-171
5. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., and Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J. Clin. Oncol. 14 (1996) 792-795
6. Muderspach L.I., Blessing J.A., and Levenback C. A phase II trial of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 81 (2001) 213-215
7. Schilder R., Blessing R.J., Morgan M., Mangan C.E., and Rader J.S. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol. Oncol. 76 (2000) 204-207
8. Muggia F.M., Blessing J.A., Method M., Miller D.S., Johnson G.A., Lee R.B., et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 92 (2004) 639-643
9. Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 22 (2004) 3113-3119
10. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J., Mc Meekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin (P) vs. cisplatin plus topotecan (T) vs. MVAC in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Gynecol. Oncol. 92 (2004) 397 [abstract]
11. Doroshow J.H. Anthracyclines and anthracenediones. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. Second ed. (1996), Lippencott-Raven Publishers, Philadelphia, PA
12. Wallace H.J., Hreshchyshyn M.M., Wilbanks G.D., et al. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat. Rep. 62 (1978) 1435-1441
13. Freedman R.S., Herson J., Wharton J.T., and Rutledge F.N. Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin. Trials 3 (1980) 345-350
14. Malkasian G., Decker D., Green S., et al. Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecol. Oncol. 11 (1981) 235-239
15. Omura G.A., Hubbard J., and Hatch K. Chemotherapy of cervix cancer with doxorubicin and cisplatin. A phase I pilot study of the Gynecologic Oncology Group. Am. J. Clin. Oncol. 8 (1985) 347-349
16. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
17. In: Huang L. (Ed). Covalently attached polymers and glycans to alter the biodistribution of liposomes. J. Liposome Res. vol. 2 (1992) 289-454
18. In: Lasic D.D., and Martin F.J. (Eds). Stealth Liposomes (1995), CRC Press, Boca Raton, FL
19. Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52 (1992) 891-896
20. Chen T.T., and Ng T. Optimal flexible designs in phase II clinical trails. Stat. Med. 17 (1998) 2301-2312
21. Rose P.G., Blessing J.A., Gershenson D.M., and McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 17 (1999) 2676-2680
22. Calero F., Rodriguez-Escuero F., Jimeno J., Mendana J., Iglesias J., Murillo F., et al. Single agent epirubicin in squamous cell cervical cancer: a phase II trial. Acta Oncol. 30 (1991) 325-327
23. Hakes T.B., Dougherty J.B., and Raymond V. Phase II study of idarubicin in advanced cervical carcinoma. Am. J. Clin. Oncol. 9 (1986) 262-263
24. Verschraegen C.F., Kavanagh J.J., Loyer E., Bodurka-Bevers D., Kudelka A.P., Hu W., et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 92 (2001) 2327-2333